Among patients with isolated systolic hypertension and frailty, antihypertensive therapy is associated with improved outcomes.

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced positive topline results from its pivotal Launch-HTN Phase 3 and ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

Hypertension (high blood pressure) effects one in three adults and is the number one cause of stroke in Northern Ireland.

Scientists have identified a widely prescribed hypertension drug as a potential key to extending lifespan and slowing aging.

High prevalence of polypharmacy and unsafe self-medication among older adults in Indian urban communities, highlighting the need for interventions.

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...

Mineralys Therapeutics’s oral hypertension therapy, lorundrostat, has met the primary endpoint in two pivotal studies, ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...

The Launch-HTN trial evaluated lorundrostat as an add-on therapy to an existing, prescribed background treatment of two-to-five anti-hypertensive medications, while the Advance-HTN trial evaluated the ...